#16
|
|||
|
|||
×òîáû ïîëó÷èòü òî÷íûé îòâåò íà ýòîò âîïðîñ ("ñêîêà" Âàì ìîæíî) îáðàòèòåòü â ñîîòâåòñòâóþùåå ìåäèöèíñêîå ó÷ðåæäåíèå äëÿ ïðîõîæäåíèÿ ñòðåññ-òåñòà (ñïèðîýðãîìåòðèÿ) ñ îñìîòðîì òåðàïåâòà. Îòâåò, âîçìîæíûé äëÿ èíòåðíåò-êîíñóëüòèðîâàíèÿ âàìè óæå ïîëó÷åí.
|
#17
|
||||
|
||||
Êîíêîð áëîêèðóåò áåòà-àäðåíîðåöåïòîðû, ïðåñòàðèóì - àíãèîòåíçèíïðåâðàùàþùèé ôåðìåíò.
Îäíîâðåìåííîå ïðèìåíåíèå âîçìîæíî. |
#18
|
||||
|
||||
|
#19
|
||||
|
||||
ÀÄ ñíèæàþò îáà. Êîíêîð óðåæàåò ×ÑÑ, ïðåñòàðèóì íå âëèÿåò íà ýòîò ïîêàçàòåëü.
|
#20
|
||||
|
||||
À êàêîâà ïðîäîëæèòåëüíîñòü äåéñòâèÿ êàæäîãî èç ïðåïàðàòîâ?
Ñïàñèáî! |
#21
|
||||
|
||||
Êàæäûé - 24 ÷àñà.
Ìîæåò áûòü Âû óæå ñôîðìóëèðóåòå âîïðîñ áîëåå òî÷íî? ×åãî êîíêðåòíî Âû õîòèòå ïîëó÷èòü â ðåçóëüòàòå êîíñóëüòàöèè? Ïîäáîð ãèïîòåíçèâíîé òåðàïèè? |
#22
|
||||
|
||||
Ìíå áûëî ïðîïèñàíî óòðîì ïðèíèìàòü êîíêîð , à âå÷åðîì ïðåñòàðèóì...
Äåëî â òîì ÷òî âå÷åðîì è íî÷üþ ìîå äàâëåíèå è òàê â ïðåäåëàõ íîðìû...áåç ïðèåìà ïðåïàðàòà...åñòü ëè ñìûñë â ïðåñòàðèóìå? |
|
#23
|
||||
|
||||
Âåðîÿòíî, Âàø äîêòîð èìåë â âèäó òîò ôàêò, ÷òî ìîíîòåðàïèÿ àðòåðèàëüíîé ãèïåðòåíçèè (â ñìûñëå ëå÷åíèå òîëüêî îäíèì ïðåïàðàòîì) - ýòî äåëî íå ñëèøêîì áëàãîäàðíîå, ò.å. åñòü ò.í. ñèíäðîì óñêîëüçàíèÿ - àêòèâèçèðóþòñÿ àëüòåðíàòèâíûå ïóòè ïîâûøåíèÿ ÀÄ è ðàíåå ýôôåêòèâíûé ïðåïàðàò ïåðåñòàåò ðàáîòàòü. Èìåííî â ñâÿçè ñ ýòèì öåëåñîîáðàçíî êîìáèíèðîâàòü äâà ëåêàðñòâà. Íî âîò íàäî ëè â Âàøåì ñëó÷àå èõ ðàçíîñèòü ïî âðåìåíè íà 12 ÷àñîâ, èëè ìîæíî ïðèíèìàòü 2 òàáëåòêè îäíîâðåìåííî - ýòî ñêîðåå âîïðîñ ê Âàøåìó ëå÷àùåìó äîêòîðó, âåðîÿòíî, ó íåãî åñòü êàêèå-òî ñîîáðàæåíèÿ.
|
#24
|
|||
|
|||
ìîæåò áûòü ýòî ìèãðåíü ?
|
#25
|
||||
|
||||
íåïîíÿòíûå ïîäâèæêè â ãðóäè
Ó ìåíÿ èçðåäêà áûâàþò íåïîíÿòíûå ïîäâèæêè â ãðóäè.
Îùóùàåòñÿ ñëåäóþùåå: ñåðäöå êàê áóä-òî ñèëüíî óäàðèò/ñîæìåòñÿ, à ïîñëå íà ìãíîâåíèå îçíîá è íåìíãî ñáèâàåòñÿ äûõàíèå.Âñå äëèòñÿ íå áîëåå ñåêóíäû. ×òî ýòî ìîæåò áûòü? |
#26
|
||||
|
||||
Íàèáîëåå âåðîÿòíî, îäèíî÷íàÿ ýêñòðàñèñòîëà, íî âîîáùå-òî - âñå, ÷òî óãîäíî.
Âîîáùå, Âàøè ïîïûòêè ïîëíîñòüþ çàìåíèòü î÷íóþ êîíñóëüòàöèþ ó âðà÷à èíòåðíåò-êîíñóëüòàöèÿìè äîñòàòî÷íî íàèâíû. Ïîðà âñå-òàêè îòîðâàòüñÿ îò ýêðàíà. |
#27
|
||||
|
||||
Ê âðà÷ó ïëàíèðóþ ïîïàñòü ÷åðåç íåäåëþ.Ïîêà ïðîñòî ïûòàþñü ïîíÿòü ÷òî ê ÷åìó.
ÝÊà äåëàë íåäåëþ íàçàä, íè÷åãî êðîìå íåïîëíîé áëîêàäû ï íîæêè ï. Ãèññà íå îáíàðóæåíî. Ò.í. ýêñòðàñèñòîëû ó ìåíÿ áûâàþò ïðèìåðíî 1 ðàç â ìåñÿö-ïîòîðà, èëè ðåæå. |
#28
|
||||
|
||||
Êàê èçâåñòíî, ó ìèãðåíè áåç àóðû åñòü ÷åòêèå êðèòåðèè - ïóëüñèðóþùèé õàðàêòåð áîëè, óíèëàòåðàëüíîñòü, óìåðåííàÿ èëè ñèëüíàÿ èíòåíñèâíîñòü áîëè è óõóäøåíèå îò îáû÷íîé ôèçè÷åñêîé íàãðóçêè. Õîòÿ áû äâà êðèòåðèÿ èç ïðåäñòàâëåííûõ. Èç ñîîáùåíèé ïàöèåíòà ýòî íå ÿâñòâóåò. À åñëè áûòü òî÷íåå, òî:
DIAGNOSTIC CRITERIA — The International Headache Society (IHS) diagnostic criteria for migraine are as follows [50] : Migraine without aura — Migraine without aura is a recurrent headache disorder that fulfills the following IHS criteria [50] : Headache attacks last 4 to 72 hours Headache has at least two of the following characteristics: unilateral location; pulsating quality; moderate or severe intensity; aggravation by routine physical activity During headache at least one of the following occurs: nausea and/or vomiting; photophobia and phonophobia At least five attacks occur fulfilling the above criteria History, physical examination, and neurologic examination do not suggest any underlying organic disease Êàê ìîäåðàòîð, ïðîøó âîçäåðæèâàòüñÿ îò ñêîðîïàëèòåëüíûõ âûâîäîâ ïî ïîâîäó äèàãíîçîâ. |
#29
|
||||
|
||||
Îäèíî÷íàÿ ýêñòðàñèñòîëèÿ áûâàåò ó âñåõ ëþäåé. Ïðîñòî íà ÝÊà åå ïîéìàòü î÷åíü òðóäíî, ïîýòîìó îáû÷íî äåëàþò ñóòî÷íîå ìîíèòîðèðîâàíèå.
|
#30
|
||||
|
||||
Öèòàòà:
ADVERSE REACTIONS SIGNIFICANT 1% to 10%: **Cardiovascular: Chest pain (1% to 2%) Central nervous system: Fatigue (dose related; 6% to 8%), insomnia (2% to 3%), hypoesthesia (1% to 2%)**Gastrointestinal: Diarrhea (dose related; 3% to 4%), nausea (2%), vomiting (1% to 2%) **Neuromuscular & skeletal: Arthralgia, asthenia (dose related; ≤ 2%) **Respiratory: Upper respiratory infection (5%), rhinitis (3% to 4%), sinusitis (dose related; 2%), dyspnea (1% to 2%) |